Podiatrists in Seminole, FL Accepting Medicare

8 Podiatrists found. Showing 1 - 8

Daniel Marc Hameroff, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 10875 Park Blvd., Ste. C, Seminole, FL 33772 Phone: 727-398-6650    Fax: 727-398-6550

West Central Podiatry Consultants, P.l. Podiatrist Medicare: Medicare Enrolled Practice Location: 10875 Park Blvd, Ste. C, Seminole, FL 33772 Phone: 727-398-6650    Fax: 727-398-6550

Dr. Robert Levine, DPM Podiatrist - Sports Medicine Medicare: Not Enrolled in Medicare Practice Location: 7730 Starkey Rd, Seminole, FL 33777 Phone: 727-399-1782    Fax: 727-393-3118

Dr. John Louis Hoffman, D.P.M. Podiatrist - Primary Podiatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 11819 109th Ct, Seminole, FL 33778 Phone: 727-422-7655    Fax: 727-395-0207

Raymond A Anderson Dpm Pa Podiatrist - Primary Podiatric Medicine Medicare: Not Enrolled in Medicare Practice Location: 8423 Seminole Blvd, Seminole, FL 33772 Phone: 727-392-0248

Florida Foot Specialist Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 10863 Park Blvd Ste A, Seminole, FL 33772 Phone: 727-398-6650

Brian Keith Hameroff, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 10875 Park Blvd, Ste. C, Seminole, FL 33772 Phone: 727-398-6650    Fax: 727-398-6550

Bryan Raymond, DPM Podiatrist - Foot & Ankle Surgery Medicare: Medicare Enrolled Practice Location: 10863 Park Blvd Ste A, Seminole, FL 33772 Phone: 727-398-6650

News Archive

Synageva BioPharma seeks FDA orphan drug designation for SBC-102 enzyme replacement therapy

Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.

GRK2 protein -a potential biomarket for heart failure

A team of cardiology researchers at Thomas Jefferson University has determined that GRK2, a protein that plays an important regulatory role in heart failure, is elevated in patients with failing hearts when compared to patients with normal heart function.

NOXXON Pharma achieves important milestone in drug discovery

NOXXON Pharma AG (NOXXON), the biopharmaceutical company focusing on the development of novel medicines based on its unique proprietary Spiegelmer® technology, announced today the achievement of an important milestone in its drug discovery and development partnership with Eli Lilly and Company.

Study on H1N1 virus to be presented at IDSA annual meeting

The 2009/2010 Influenza A (H1N1) is one of several viruses responsible for respiratory-related infections. A new study from Rhode Island Hospital examined patients with viruses and found distinguishing characteristics of the H1N1 virus in how it affects respiratory illness. Their findings will be presented at the annual meeting of the Infectious Diseases Society of America to be held in Vancouver, Canada on Friday, Oct. 22.

The Parkinson's Disease Foundation and the Davis Phinney Foundation jointly fund new study

The Davis Phinney Foundation, a non-profit organization dedicated to improving the lives of people with Parkinson's disease (PD) today, announced that it has awarded four Parkinson's disease research centers with support to conduct a landmark study on the long-term changes in quality of life and mobility that occur in people with PD. The results of this research will help to advance the understanding of how interventions, such as exercise, impact changes in quality of life and mobility over the course of the disease.

Read more Medical News

› Verified 9 days ago